The Borno Polio Outbreak Response team supports vaccination in all partially accessible and inaccessible settlements and ensures at least 90% of these settlements are reached by security access teams for vaccination with bOPV. Also, the team supports Borno EOC to consolidate all PEI datasets, use data for action and build the capacity of state staff on the EOC M&E team.
Impact:
Through this project, 99.6% (4,332) of 4,353 partially accessible settlements were visited and 279,994 unique under-5 children vaccinated with bOPV using the Reaching Every Settlement (RES) strategy before being successfully transitioned to the state. 71% (5,055) of 7078 inaccessible settlements have been visited with 126,168 unique u-5 children vaccinated with bOPV using the BI/RIC strategy and additionally, access teams reached 2,511 inaccessible settlements and vaccinated 34,165 u-5 children using mOPV2. The Solina team also supported Borno state’s documentation to the African Regional Certification Commission (ARCC) leading to Nigeria and Africa being certified Wild Polio Virus-free. The team coordinated the activities of the data team and supported the Borno EOC to analyse and visualize SIA campaigns and other special interventions data and use these data to make informed decisions, estimate and monitor the number of u-5 children living in areas unreached with vaccination and surveillance. So far, the number has reduced from 432,245 in September 2016 to 24,994 by December 2020. Solina tracks and monitors sporadic and sustained surveillance for Acute Flaccid Paralysis (AFP). Thus far, only 616 (3%) of 22,663 geo-locations across the state remain unreached by any form of surveillance. Solina also manages the Master List of Settlements which is used to plan PEI activities in light of changing habitation and accessibility status of the settlements
SCIDaR contributed to the eradication of Polio in Africa as on the 25th of August 2020, after four (4) years without a single case of wild polio, the African region was certified free of wild poliovirus and we will continue to partner to reduce the risk of emerging infectious diseases.
